This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Springate, J. E. Articles by Ganten, D. Search for Related Content PubMed PubMed Citation Articles by Springate, J. E. Articles by Ganten, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ENALAPRIL MALEATE Medline Plus Health Information High Blood Pressure

(Hypertension. 1997;30:868-872.)
© 1997 American Heart Association, Inc.

Articles

Enalapril and Renal Function in Hypertensive Rats Transgenic for Mouse Renin Gene

James E. Springate; Leonard G. Feld; ; Detlev Ganten

From the Departments of Pediatrics and Physiology, State University of New York at Buffalo School of Medicine and Biomedical Sciences; Buffalo Veterans Affairs Medical Center; The Children's Hospital, Buffalo, NY; and Max Delbruck Center for Molecular Medicine, Berlin-Buch, Germany.

Abstract We examined the effect of long-term enalapril treatment on renal function and histology in the monogenetically hypertensive TGR(mRen2)27 rat strain. Untreated transgenic rats had significantly (P<.01) higher blood pressures than treated transgenic and control animals throughout the study. Urinary nitric oxide metabolite excretion was significantly lower in young transgenic rats and rose with enalapril, suggesting abnormal TGR nitric oxide production and its correction by enalapril. Converting enzyme inhibition produced preferential preglomerular vasodilatation and increased renal blood flow (6.5±0.5 versus 9.0±0.7 mL/min per gram kidney weight, P<.05) without altering whole-kidney and single-nephron glomerular filtration rates in TGR(mRen2)27. Glomerular capillary pressure fell modestly in treated transgenic animals (54±1 versus 50±1 mm Hg, P<.05). These hemodynamic changes were associated with reductions in albuminuria (59±6 versus 9±2 mg/d, P<.01) and glomerulosclerosis in TGR. However, urinary albumin excretion (15±3 versus 3±1 mg/d, P<.05) and glomerulosclerosis also declined in treated control animals in the absence of significant alterations in glomerular hemodynamics. The mechanism of the beneficial effect of enalapril on the TGR(mRen2)27 kidney is unclear but could involve either control of hypertension or suppression of the intrarenal renin-angiotensin system.

Key Words: glomerulosclerosis • albuminuria • nitric oxide

This article has been cited by other articles:

				E. VanBavel and M. J. Mulvany Integrins in Hypertensive Remodeling Hypertension, February 1, 2006; 47(2): 147 - 148. [Full Text] [PDF]

				S. M. Jacinto, J. J. Mullins, and K. D. Mitchell Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats Am J Physiol Renal Physiol, February 1, 1999; 276(2): F315 - F322. [Abstract] [Full Text] [PDF]